Cita APA

Rangachari, D., Le, X., Shea, M., Huberman, M. S., VanderLaan, P. A., Kobayashi, S. S., & Costa, D. B. (2017). Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy. J Thorac Oncol.

Chicago Style Citation

Rangachari, Deepa, Xiuning Le, Meghan Shea, Mark S. Huberman, Paul A. VanderLaan, Susumu S. Kobayashi, i Daniel B. Costa. "Cases of ALK-rearranged Lung Cancer With 5-year Progression-free Survival With Crizotinib As Initial Precision Therapy." J Thorac Oncol 2017.

Cita MLA

Rangachari, Deepa, et al. "Cases of ALK-rearranged Lung Cancer With 5-year Progression-free Survival With Crizotinib As Initial Precision Therapy." J Thorac Oncol 2017.